Belgium’s Galapagos NV, which specialises in developing drugs for bone and joint diseases, expects to file an investigational new drug application (IND) by the end of 2008 for Nanocort, a liposome-formulation of the corticosteroid, prednisolone. The drug is being developed to treat flares in rheumatoid arthritis.
